Meet the team: Leo James, Co-founder and Chief Scientific Adviser, TRIMTECH Therapeutics
17 February 2026 – Read news
TRIMTECH Therapeutics wins ‘Seed Raise of the Year’ at the 2025 European Lifestars Awards
17 November 2025 – Read news
Meet the team: Andrea Testa, Senior Director of Chemistry
05 November 2025 – Read news
TRIMTECH Therapeutics wins ‘Start-up of the Year’ at the 2025 TPD & Induced Proximity Awards
17 November 2025 – Read news
TRIMTECH Therapeutics featured in Clarivate’s report highlighting six companies advancing targeted protein degradation
07 October 2025 – Read news
Introducing Fierce Biotech’s 2025 Fierce 15
22 September 2025, Fierce Biotech – Read news
Nicki Thompson interview with Drug Discovery World
8 July 2025, Drug Disovery World – Read news
Academic co-founder, Leo James elected to Royal Society
20 May 2025, MRC Laboratory of Molecular Biology (LMB) website – Read news
Nicki Thompson, CEO talks with BiotechTV at BioTrinity 2025
02 April 2025, BiotechTV – Watch video
Lilly, Pfizer invest in UK startup’s seed round for neurodegeneration protein degraders
05 March 2025, Endpoints News – Read news
© TRIMTECH Therapeutics
TRIMTAC, TRIMVEC and TRIMGLUE are registered trademarks of TRIMTECH Therapeutics Ltd.
Nicki Thompson talks with BiotechTV at BioTrinity 2025
Nicki Thompson, TRIMTECH Therapeutics Limited’s CEO, gave an oral presentation at BioTrinity 2025. In this post from BiotechTV she reviews the unique properties of TRIM21 that make it so powerful for selectively degrading protein aggregates while leaving soluble protein unaffected.